{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000184","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.486676+00:00","generated_at":"2026-06-07T00:51:56.697142+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bio-Path completes first dose cohort in Phase 1 trial of BP1002 for lymphoma/CLL","bullets":["BP1002, a liposomal Bcl-2 antisense, advanced to next dose cohort (40 mg/m²) after completing 20 mg/m² cohort safely.","Trial targets refractory/relapsed lymphoma and CLL patients, including those who failed venetoclax-based therapy.","Phase 1 uses 3+3 design; six evaluable patients per cohort; enrollment open for second cohort.","BP1002 targets Bcl-2 mRNA, potentially overcoming BH3 domain mutations causing venetoclax resistance."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000184","json":"https://secwatch.observer/filing/0001558370-24-000184.json","markdown":"https://secwatch.observer/filing/0001558370-24-000184.md","text":"https://secwatch.observer/filing/0001558370-24-000184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024000184/0001558370-24-000184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024000184/bpth-20240110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:51:56.697142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}